Clarity Secures Three-Year Copper-67 Supply from Nusano’s Utah Facility

Strategic Supply Partnership

Clarity Pharmaceuticals (ASX – CU6), a clinical-stage radiopharmaceutical company focused on cancer therapies, has announced a significant supply agreement with Nusano, Inc. for copper-67, a therapeutic isotope central to Clarity’s clinical and commercial ambitions. The three-year deal, effective immediately, will see Nusano provide copper-67 from its cutting-edge accelerator-based production facility in West Valley City, Utah, starting mid-2026.

This partnership is a strategic move to secure a reliable and scalable supply of copper-67, which is essential for Clarity’s lead product, Cu-SAR-bisPSMA. This radiopharmaceutical is currently progressing towards a registrational Phase III clinical trial targeting prostate cancer, a disease area with substantial unmet medical needs. The product has already received Fast Track Designation from the US Food and Drug Administration, underscoring its potential impact.

Innovative Production Methods

Nusano’s facility employs proprietary accelerator-based technologies that enable high-volume mass production of copper-67. Unlike traditional isotope production reliant on aging nuclear reactors, this method requires only electricity and readily available starting materials, offering a more sustainable and cost-effective supply chain. Nusano is also developing its own enriched stable isotope production, further mitigating supply risks and ensuring a fully integrated US-based production process.

Clarity’s Executive Chairperson, Dr Alan Taylor, highlighted the importance of diversifying supply sources to avoid the bottlenecks experienced with other isotopes like lutetium-177. He emphasized that accelerator-based production is a prerequisite for sustainable growth in radiopharmaceuticals, enabling rapid scale-up to meet clinical and commercial demand.

Expanding US Supplier Network

This agreement with Nusano complements Clarity’s existing network of US suppliers, including NorthStar Medical Radioisotopes and Idaho State University’s Idaho Accelerator Center. By building a robust and diversified supply chain, Clarity aims to ensure uninterrupted access to copper-67, critical for both ongoing clinical trials and eventual market supply.

Nusano’s CEO, Chris Lowe, expressed enthusiasm about supporting Clarity’s unique position as the only radiopharmaceutical company with active clinical trials using copper-67. He underscored Nusano’s commitment to advancing radioisotope production technologies that not only support healthcare innovation but also enhance national security by reducing foreign supply dependencies.

Looking Ahead

While the supply agreement solidifies a key component of Clarity’s development strategy, commercial availability of Cu-SAR-bisPSMA remains contingent on regulatory approvals. The company’s ability to scale manufacturing swiftly upon trial success will be critical to capturing market opportunities in prostate cancer treatment.